Safingol

Drug Profile

Safingol

Alternative Names: Kynac; Kynacyte; L-threo-Dihydrosphingosine; SPC 100270

Latest Information Update: 14 Mar 2008

Price : $50

At a glance

  • Originator Research Triangle Park Laboratories
  • Developer Eli Lilly; Research Triangle Park Laboratories
  • Class Chemosensitisers
  • Mechanism of Action Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atopic dermatitis; Cancer; Psoriasis

Most Recent Events

  • 27 Apr 2001 Sphinx Pharmaceuticals is now called Sphinx Laboratories
  • 16 Jun 1999 A preclinical study has been added to the Cancer pharmacodynamics section
  • 28 May 1997 Phase-II clinical trials for Cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top